MedTechIQ_3Helix InSight Engine-Beta
Preview
Open in TheBrain
Triple Helix Discovery Engine
*Driving Forces: Market Research, Intelligence, Analysis, Datapoints, Databases & Trends
*Driving Forces: Biotechnology_Natural Killer Cell Therapies
Medical Science & Technology
Blood Research
Parents
Diagnostics (Dx)
Medical Science & Technology
Children
“Lab-on-a-Chip” clinical diagnostics technology, U of Cincinnati
**Key People: DOD_DHA_USAMRDC (U.S. Army Medical Research and Development Command), formerly, USAMRMC (U.S. Army Medical Research and Material Command)
*Blood & Resuscitation Products, CCC (Combat Casualty Care):USAMRMC
*Blood Safety and Decontamination
*Funding: Laboratories_Equipment, Facilities, Biorepository, Laboratory Information Systems (LIS)_Blood, Hemorrhage, Hematology, Hemostasis, Microscopy, Pathology Technology, Assays, Reagents & Devices
*Funding: Laboratories_Equipment, Laboratory Information Systems (LIS)_Blood, Hemorrhage, Hematology, Hemostasis, Microscopy, Pathology Technology, Assays & Devices (Archives 2010-2016)
*Funding: Laboratories_Equipment, Laboratory Information Systems (LIS)_Blood, Hemorrhage, Hematology, Hemostasis, Microscopy, Pathology Technology, Assays & Devices (Archives 2017-2020)
*Pioneers: Blood Management
*Pioneers: Blood Research_Hemorrhage, Clots, Etc.
*Pioneers: Diagnostics_Sensors / Blood Analyzers
*Pioneers: Hemorrhage, Hemostasis
*Pioneers: Medical Imaging_Telepathology
*Pioneers: MEMS-Micro Electronic Machines, MicroFluidics
2010: The Blood Test Gets a Makeover (2010)
2011: Lab-on-Chip Developed for Detection of Vascular, Cardiac Diseases (2011)
2012: Tech Diagnostics Help Rural Areas (2012)
2014: American Society of Hematology Accepting Applications for Bridge Grant Program
2014: CDC-RFA-DD-14-003: Pilot Interventions to Promote the Health of People with Blood Disorders = $600,000/2 - Mar 11, 2014
2014: CDC-RFA-DD14-1408: Hemoglobinopathies Surveillance, Health Promotion, and Laboratory Capacity Demonstration Project -DD12-1206 = $2,000,000/3 - Closing Date for Applications: Mar 14, 2014
2014: CDC-RFA-DD14-1409:Public Health Surveillance for the Prevention of Complications of Bleeding and Clotting Disorders=$4,200,000/3 - Apr 8, 2014
2014: DOD-DHP14-004: Rapid Indicator of Potential for Weight Gain/Loss & Trending =$1,250,000 - 22 January 2014
2014: DOD-DHP14-005: Development of a Multiplex Bioassay for Early Predictors of Multiple Organ Injury =$1,250,000 - 22 January 2014
2014: HHS SBIR PA-11-340: Development of novel and emerging technologies for the accurate detection and diagnosis of polymicrobial infections in biomedical laboratory animal models= $1,250,000 - September 8, 2014
2014: HHS STTR PA-11-341: Development of novel and emerging technologies for the accurate detection and diagnosis of polymicrobial infections in biomedical laboratory animal models= $1,250,000 - September 8, 2014
2014: HHS-NIH-NIDA(SSSA)-2014-086: NIH Neurobiobank Tissue Toxicology (Sources Sought) = $ - Response Date: Mar 06, 2014
2014: NASA-NSBRI-RFA-14-01: Administering health care in space demands innovative biomedical solutions =$100,000/matching - 13 Feb, 13 May, 13 Aug, 13 Nov: Deadline-Aug. 7, 2014
2014: NSF-14-539 - SBIR (Small Business Innovation Research Program) - June 10, 2014: BM6. Diagnostic Assays and Platforms
2014: NSF-14-539 - SBIR (Small Business Innovation Research Program) - June 10, 2014: BT3. Life Sciences Research Tools
2014: NSF-14-539 - SBIR (Small Business Innovation Research Program) - June 10, 2014: BT4. Bioinstrumentation
2014: State-Based Public Health Laboratory Biomonitoring Programs=$5,000,000/5 - Closing Date for Applications:May 6, 2014
2014:CDC-RFA-DD14-1405-Evaluation of Health Promotion and Prevention Programs for Blood Disorders=$1,500,000/4-May 21, 2014
2015: NHLBI-RFA-HL-14-011:Onsite Tools and Technologies for Heart, Lung, and Blood Clinical Research Point-of-Care SBIR (R43/R44)=$1,725,000 - Letter of Intent: March 16, 2014; September 15, 2014; March 16, 2015; September 15, 2015
2015: NIH-NHLBI-RFA-HL-15-022: Stem Cell-Derived Blood Products for Therapeutic Use (R01)=$1,200,000/8 : Letter of Intent Due Date(s)-January 20, 2015
2015: NIH-NHLBI-RFA-HL-15-029: Stem Cell-Derived Blood Products for Therapeutic Use: Technology Improvement (R41)=$ 1,225,000/3 : Letter of Intent Due Date(s)-January 20, 2015
2016: NIH-NCI-RFA-HL-15-030: Stem Cell-Derived Blood Products for Therapeutic Use: Technology Improvement (R43/R44)=$1,225,000 : Letter of Intent - January 20, 2015 (Phase I or Fast-Track); January 20, 2016 (Phase I; Phase II; or Fast-Track)
2016: NIHLBI-RFA-HL-14-017: Onsite Tools and Technologies for Heart, Lung, and Blood Clinical Research Point-of-Care STTR (R41/R42)=$1,250.000 - October 15, 2014; October 15, 2015, October 15, 2016:Expiration: October 16, 2016
2016: PA-13-302-NIH-Research Project Grant (Parent R01)= $2,500.000:February 5, June 5, October 5: Expiration Date - September 8, 2016
2017: U.S. Army_Blood, Blood Products and Blood Exchange Services
2018: CDMRP_Department of Defense Bone Marrow Failure Research Program Anticipated Funding Opportunities for Fiscal Year 2018 (FY18)
2019: CDC-RFA-DD19-1903_Characterizing the Complications Associated with Therapeutic Blood Transfusions for Hemoglobinopathies
2019: DHA_MHS Vendor Day: Focus on capability to draw, store, transfuse, and transport fresh whole blood
2019: FDA REGULATED BLOOD AND BLOOD PRODUCTS FOR TRANSFUSION MEDICINE
2019: MTEC_Army Consortium Wants Cutting-Edge Hemorrhage Detection Technology
2019: MTEC_Pre-Announcement for Mobile Application Development Proof of Concept - Theater Blood RPP
2020: VA_Sustainment of Blood Bank Maintenance - VBECS modification
2021: FDA_Integrated Pathogen Reduction Technologies for whole blood and blood components for transfusion (R01) Clinical Trials Not Allowed
2021: Laser Kills Multidrug-Resistant Bacteria for Wound and Blood Decontamination
2022: HRSA_National Hemophilia Program Coordinating Center
2024: NHLBI SBIR Phase IIB Small Market Awards to Accelerate the Commercialization of Technologies for Heart, Lung, Blood, and Sleep Disorders and Diseases (R44 Clinical Trial Optional)
2024: NHLBI_Physician Scientist Transition to Independence in Blood Science Research (R00
2024: NIDDK_Stimulating Hematology Investigation: New Endeavors (SHINE) (R01 Clinical Trial Not Allowed)
2025: NHLBI_NOSI_IDEA2Health: Innovative Data Evaluation and Analysis to Health
2025: NHLBI_NOSI: Examining Effects of HIV Pre-Exposure Prophylaxis (PrEP) on Heart, Lung, Blood, and Sleep Function
Access Scientific
AccuVein
Actinobac Biomed
ADS Biotechnology Corp
Aethlon Medical, Inc. (NASDAQ: AEMD)
Akebia Therapeutics Inc. (NASDAQ: AKBA)*
Alung Technologies, Inc.
American Society for Microbiology
Architects: Blood Processing, Blood Pumps, Diagnostics, Hemorrhage, Bleeding, Hemostatis, Transfusion, Intravenous (IV) Management
Architects: Cardiovascular & Cardiology Companies _ Pharmaceutical & Biotechnology _ Fats & Cholesterol
Architects: Cardiovascular, Cardiac & Cardiology Companies _ Pharmaceutical & Biotechnology
Arcos, Inc.
Arteriocyte Medical Systems, Inc.
Artisan Pharma Inc
Automated Laboratory Testing
Automated multiplane microscopy-Burnham Institute for Medical Research
Battlefield Blood Samples Preparation
Biotime (NYSEMKT:BTX)
BioVascular, Inc
Blood Systems Research Institute
BMIST:Blood Information Program
Cellerant Therapeutics
Cerus Corporation (NASDAQ:CERS)*
Cheetah Medical
CytoSorbents Corporation (NASDAQ:CTSO)*
Engineering innovative mChip hand-held lab-on-a-chip could streamline blood testing worldwide (2011)
Entegrion, formerly Hemocellular Therapeutics
Evaluation of the Array Microscope for Telepathology (2004011134)
ExoStat Medical
Field Blood Bank/Blood Inventory Program (BIP) (2004011135)
Flow Cytometry
Fluidnet
General Blood
Global Blood Therapeutics Inc. (NASDAQ: GBT)
Hema Metrics
HemaQuest Pharmaceuticals, Inc.
HEMCON-Hemorraghe Control Technologies
Hememics Biotechnologies, Inc.
Iggbo
Lab on a Chip Technology
Lifebond
Linebacker, formerly SyberMed Enterprises
Low Power Blood Cooling & Storage
Micro- and Nano-Fluidic Channel Based Lab-on-a-Chip Technologies-University of Pennsylvania
Molecular Diagnostic Laboratory
Navilyst Medical Inc
New Health Sciences
On-Qi-ity
OrSense
Oxygen Biotherapeutics (Nasdaq: OXBT)
Pathology Core-UTHSC
Pioneers: Laboratory & Blood Technology Research
Polyheme Blood Subsitute
ProFibrix, B.V.
Prolong Pharmaceuticals
Quotient Biodiagnostics
Quotient Limited (QTNT)
Radio Frequency Identification system (RFID) implantation
Rare Blood Program
Red Cross International
Regado Biosciences, Inc.- RGDO
Retractable Technologies, Inc. (NYSE:RVP)
Sangamo Therapeutics, Inc. (NASDAQ:SGMO)*
Sangart
SEA Medical Systems, Inc.
SequanaMedical (formerly Novashunt)
Seventh Sense Biosystems
SIB Medical Technologies: Accelerate Michigan 2013 Entry
SMT Research and Development Ltd. (SMT)
Soluble Therapeutics
Speer Medical Devices
St. Teresa Medical
STB (“Stop The Bleeding”) Lifesaving Technologies
SyberMed Enterprises
Synthetic Blood International, Inc.
T2 Biosystems, Inc. (NASDAQ: TTOO)*
Talecris (Nasdaq: TLCR) Biotherapeutics
Telechemistry for Theater Army Med Lab(TAML)-USAMRICD
Tem Systems
The Medicines Company (NASDAQ: MDCO)
Thermedx
ThromboVision
Transportable Pathogen Reduction & Blood Safety System
Tropical Medicine and Telemedicine Center of Excellence
Wellsky, formerly, Mediware Info Systems (MEDW)
Jumps
Breath Analysis, Breathalyzers
Hydration
Saliva
Sweat
Urine